The Hepatitis B Package measures key markers related to the hepatitis B virus (HBV) to assess infection status and immune response. It includes the Hepatitis B Surface Antigen (HBsAg), which indicates an active infection, and the Hepatitis B Core IgM Antibody, suggesting a recent infection. The package also tests for Hepatitis B e Antibody (anti-HBe), indicating recovery from infection and a lower risk of transmission and Hepatitis B e Antigen (HBeAg), signifying active replication and higher infectivity. Additionally, Hepatitis B Surface Antibody (anti-HBs) reflects recovery or immunity from vaccination, while Hepatitis B Core Total Antibody (anti-HBc) indicates past or present infection. By analyzing these biomarkers collectively, doctors can tailor treatment strategies, monitor disease progression, and optimize patient outcomes, improving liver health and preventing long-term complications associated with hepatitis B.
The Hepatitis B Surface Antigen (HBsAg) test detects HBsAg, a protein on the surface of the hepatitis B virus (HBV), in the blood. It is an important screening test for HBV infection. A reactive result needs follow-up with additional tests, such as anti-HBs and total anti-HBc antibodies, and can be confirmed with HBV DNA testing by PCR. This test helps identify individuals who may need medical treatment and supports measures to prevent the spread of hepatitis B. The test uses automated chemiluminescence immunoassay (CMIA/CLIA) technology, which may vary slightly across laboratories.
Know more about Hepatitis B Surface Antigen (HBsAg)
The HBeAg (Hepatitis B Envelope Antigen) test measures the presence of the HBeAg in the blood, indicating active viral replication. A positive result signifies that the virus is replicating at a high level, suggesting a higher risk of transmission to others and potential progression to more severe liver disease. Conversely, a negative result may indicate lower viral activity or that the virus is in a non-replicative state.
Understanding the significance of HBeAg status is crucial in managing chronic hepatitis B infection. It helps guide treatment decisions, informs about the potential for liver damage, and aids in assessing the effectiveness of therapeutic interventions. Regular monitoring through this test can play a pivotal role in maintaining liver health and preventing complications associated with chronic hepatitis B.
Know more about HBeAg (Hepatitis B Envelope Antigen)
The Hepatitis B Package is done:
- To confirm the presence of hepatitis B virus in individuals showing symptoms of hepatitis B such as stomach pain, joint pain, dark-colored urine, light-colored stool, and the yellowing of skin and eyes (jaundice) or at risk of infection.
- To determine whether the infection is acute or chronic based on specific antibodies and antigen markers.
- To determine if an individual is currently infected with hepatitis B or has been exposed in the past.
- To evaluate active viral replication, which can influence treatment decisions and transmission risk.
- To assess whether an individual has recovered from hepatitis B or achieved immunity through vaccination.
- To identify individuals who may require further monitoring or treatment to prevent liver damage or complications.
- To assess the need for antiviral therapy and evaluate liver function.
- To proactively test individuals at higher risk, such as pregnant women and those with liver disease.
- No special preparation is required.
